Physician profile
Kevin L Jackson
NPI 1316938517
$1,925.20
in general payments reported to CMS, 2019-2025
33 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $585 · 2021: $563 · 2022: $98.91 · 2023: $334 · 2024: $87.85 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.01 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $296.27 | 2020-2022 | |
| Astellas Pharma US INC | $268.03 | 2021-2023 | Veozah |
| Novo Nordisk INC | $134.71 | 2019-2024 | Wegovy |
| Lilly USA, LLC | $115.71 | 2020-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.63 | 2020-2021 | |
| Amarin Pharma, INC. | $108.34 | 2019-2021 | |
| Abbvie INC. | $78.62 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $75.81 | 2020 | |
| Novartis Pharmaceuticals Corporation | $74.53 | 2019-2023 | |
| Boston Scientific Corporation | $65.42 | 2023-2025 | Watchman Access System, Watchman Flx |
| Merck Sharp & Dohme LLC | $60.84 | 2020 | |
| Amgen INC. | $53.48 | 2020-2023 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $52.95 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $48.43 | 2021-2023 | |
| Exact Sciences Corporation | $39.02 | 2023-2025 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $38.70 | 2019-2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $33.85 | 2023 | Quviviq |
| Radius Health, INC. | $23.34 | 2023 | Tymlos |
| Inspire Medical Systems, INC. | $23.15 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $22.38 | 2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $21.50 | 2023 | Rexulti |
| Hikma Pharmaceuticals USA | $20.03 | 2022 | |
| Genentech USA, INC. | $18.87 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.03 | 2022 | |
| Vistapharm, INC. | $16.20 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.59 | 2024 | Nuzyra |
| Metacel Pharmaceuticals LLC | $13.94 | 2025 | Ozobax |
| Daiichi Sankyo INC. | $13.61 | 2021 | |
| Esperion Therapeutics, INC. | $13.58 | 2020 | |
| Allergan, INC. | $13.42 | 2020 | |
| Biogen, INC. | $13.09 | 2020 | |
| Glaxosmithkline, LLC. | $12.62 | 2019 | |
| Athena Bioscience, LLC | $10.51 | 2023 | Qdolo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.